SCHEMBL5215797

SCHEMBL5215797

CC(C)(C)OC(=O)N1CCC(C(=O)c2ccc(OCC(=O)O)c([N+](=O)[O-])c2)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
STS P08842 4/20 0.43
PDE4A P27815 2/20 0.42
PDE4B Q07343 2/20 0.42
PDE4C Q08493 2/20 0.42
PDE4D Q08499 2/20 0.42
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41
ABL1 P00519 1/20 0.41
RIN1 Q13671 1/20 0.41
KDM4E B2RXH2 2/20 0.40
PKM P14618 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369253 0.91 STS (0.46) GPR119KMT2ASTSPDE4APDE4B
SCHEMBL5215440 0.83 GPR119 (0.49) GPR119KMT2ASTSALDH1A1LMNA
SCHEMBL5215281 0.83 GPR119 (0.49) GPR119KMT2AMEN1STSPDE4A
SCHEMBL5217071 0.81 MAPT (0.59) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL19423770 0.80 KDM4E (0.55) KMT2AMEN1STSALDH1A1LMNA
SCHEMBL5217654 0.80 USP30 (0.44) GPR119KMT2AMEN1PDE4APDE4B
SCHEMBL5214477 0.79 GPR119 (0.42) GPR119KMT2AMEN1ALDH1A1MAPT
SCHEMBL5215828 0.79 PDE4B (0.48) KMT2AMEN1PDE4BALDH1A1KDM4E
SCHEMBL4432015 0.78 MAPT (0.53) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL5253946 0.76 CHEK2 (0.44) GPR119KMT2AMEN1PDE4BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1330460-B1 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM PLC (GB) 2007-03-21 EP disclosed
US-6939871-B2 Benzoxazinone derivatives, their preparation and use SMITHKLINE BEECHAM P.L.C. (GB) 2005-09-06 US disclosed
US-20040063704-A1 Benzoxazinone derivatives, their preparation and use SMITHKLINE BEECHAM P.L.C (GB) 2004-04-01 US disclosed
EP-1330460-A2 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM PLC (GB) 2003-07-30 EP disclosed
WO-2002034754-A2 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM P.L.C. (GB) 2002-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063704-A1 Benzoxazinone derivatives, their preparation and use CYP2B6, CBR1, CYP2A6 GPR119 1394/4885KMT2A 2934/4885MEN1 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.